SUFFOLK, U.K., May 20, 2002 (PRIMEZONE) -- GeneMedix plc, ("GeneMedix" or "the Company") (LSE:GMX), the U.K. generic biopharmaceutical company with operations in Europe and Asia and with joint London and Singapore Stock Exchange listings, announces its results for the 3 months to February 28, 2002. GeneMedix is involved in the development and manufacture of therapeutic proteins using recombinant DNA technology and novel cell culture.
Key highlights for the period:
-- Continued development of global manufacturing and distribution
infrastructure
-- Product development on schedule
-- First product launched in China, initial sales made
-- Irish plant construction progressing, mechanical completion
expected June
-- Cash balances at period end 10.96 million pounds; all projects
remain within budget
Post period event:
-- Manufacturing and distribution agreements signed to cover India
To view the full press release please click on the link: http://reports.huginonline.com/859824/103890.pdf